Wealth Enhancement Advisory Services
ALDX icon

Wealth Enhancement Advisory Services’s Aldeyra Therapeutics ALDX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.4K Sell
47,518
-13,569
-22% -$23.3K ﹤0.01% 3796
2026
Q1 		$101K Buy
61,087
+28,404
+87% +$124K ﹤0.01% 3319
2025
Q4 		$133K Sell
32,683
-159
-0.5% -$817 ﹤0.01% 3374
2025
Q3 		$184K Buy
32,842
+5,556
+20% +$29K ﹤0.01% 3168
2025
Q2 		$117K Buy
27,286
+16,376
+150% +$42.3K ﹤0.01% 3113
2025
Q1 		$62.7K Buy
+10,910
New +$64.5K ﹤0.01% 2834

Other funds holding ALDX

AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
WC
Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Wealth Enhancement Advisory Services's ALDX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Aldeyra Therapeutics (ALDX) stake by 22% in Q2 2026, selling an estimated $23.3K and leaving 47,518 shares worth $98.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3796.

Wealth Enhancement Advisory Services first reported a position in ALDX in Q1 2025 and has held it in 6 quarters since. The position peaked at $184K in Q3 2025. 10 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Wealth Enhancement Advisory Services held 47,518 shares of Aldeyra Therapeutics worth $98.4K as of Q2 2026.
  • Wealth Enhancement Advisory Services sold 13,569 Aldeyra Therapeutics shares in Q2 2026, an estimated $23.3K.
  • Aldeyra Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3796 holding.
  • Wealth Enhancement Advisory Services first reported a position in Aldeyra Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Wealth Enhancement Advisory Services's Aldeyra Therapeutics position peaked at $184K in Q3 2025.
  • 10 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.